Confronting pharma, Trump admin seeks price disclosure in drug ads

HHS chief Alex Azar announced the much-anticipated proposal Monday, dismissing a new pledge from trade lobby PhRMA as insufficient.

By Ned Pagliarulo , Andrew Dunn • Updated Oct. 15, 2018

Under pressure, drugmakers give an inch on DTC drug ads

Members of the trade group PhRMA will soon point consumers to drug cost information in direct-to-consumer TV ads, but won't go so far as to include prices upfront.

By Ned Pagliarulo • Updated Oct. 15, 2018

Gilenya beats Copaxone head-to-head at higher dose, study finds

The multiple sclerosis drugs are top-sellers for their respective makers, Novartis and Teva. Yet a Phase 3b trial showed an efficacy edge for Gilenya.

By Andrew Dunn • Oct. 11, 2018

Price increases on top drugs drove majority of recent growth, analysis finds

Over the past three years, roughly 60% of the growth in U.S. sales for four dozen top-selling drugs came via price increases, according to numbers crunched by investment firm Leerink.

By Ned Pagliarulo • Oct. 10, 2018